



Identification of a Novel *bla*_{NDM} Variant, *bla*_{NDM-33}, in an *Escherichia coli* Isolate from Hospital Wastewater in China

Tao Wang,^a Yuan Zhou,^b Chunhong Zou,^c Zhichen Zhu,^a Jie Zhu,^a Jingnan Lv,^a Xiaofang Xie,^a Liang Chen,^{d,e} Siqiang Niu,^c Hong Du^a

^aDepartment of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

^bDepartment of Ophthalmology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

^cDepartment of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

^dHackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA

^eDepartment of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA

Tao Wang, Yuan Zhou, and Chunhong Zou contributed equally to this work. The order of authors was determined by discussion and mutual agreement between the three authors.

ABSTRACT Since the discovery of NDM-1 and the worldwide reporting of different variants have raised alarms concerning global health, the problem of carbapenem-resistant *Enterobacterales* (CRE) has become increasingly serious. Therefore, research on the hydrolytic activity and molecular structure of NDM variants is beneficial to the development of antibacterial drugs. NDM has been evolving into variants that possess different hydrolysis activities toward β -lactam antibiotics. Here, we characterized a novel *bla*_{NDM} variant, named *bla*_{NDM-33}, identified from a multidrug-resistant *Escherichia coli* strain from hospital sewage. NDM-33 differed from NDM-5 with a single-amino-acid substitution (A72T). *bla*_{NDM-5} was located in the Tn125-related *bla*_{NDM-33} region from an IncX3-type plasmid, pH6415-NDM, that can be transferred horizontally. The genetic construct of *bla*_{NDM-33} showed higher MICs of carbapenems than a *bla*_{NDM-5} construct. Enzyme kinetics showed that NDM-33 had higher enzymatic activity for meropenem and cefazolin than NDM-5. The emergence of this novel NDM variant could pose a threat to public health because of its transferability and enhanced carbapenem activity.

IMPORTANCE Our study described a novel NDM-33 variant from an *E. coli* strain isolated from hospital sewage, where it was associated with human disease and antibiotic exposure. Importantly, hospital sewage was increasingly considered to be related to CRE hosts. Pathogens were transmitted from reservoirs through direct and indirect contact, ingestion, and inhalation of contaminated water or aerosols. In addition, under the selective pressure of antibiotics, NDM variants will become the main strain in the hospital water system and evolve into high virulence and high resistance. The monitoring of NDM mutants is of great significance for preventing and controlling the evolution of superbugs.

KEYWORDS CRE, *E. coli*, *bla*_{NDM-33}, hospital sewage

The prevalence of carbapenem-resistant *Enterobacterales* (CRE) has increased since the early 2000s, representing a tremendous public health threat (1). NDM-1 was first detected in a *Klebsiella pneumoniae* isolate from a Swedish patient with urinary tract infection who traveled to New Delhi in 2008 (2). Since then, 32 NDM variants have been described or the sequences have been deposited in the GenBank database (<https://www.ncbi.nlm.nih.gov/>). Among them, the NDM-5 variant was first found in a multidrug-resistant *Escherichia coli* ST648 isolate recovered from the perineum and throat of a patient in the United Kingdom, and it showed enhanced hydrolytic activity compared with NDM-1

Citation Wang T, Zhou Y, Zou C, Zhu Z, Zhu J, Lv J, Xie X, Chen L, Niu S, Du H. 2021. Identification of a novel *bla*_{NDM} variant, *bla*_{NDM-33} in an *Escherichia coli* isolate from hospital wastewater in China. *mSphere* 6:e00776-21. <https://doi.org/10.1128/mSphere.00776-21>.

Editor Patricia A. Bradford, Antimicrobial Development Specialists, LLC

Copyright © 2021 Wang et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Hong Du, hong_du@126.com, or Siqiang Niu, siqiangniu@cqmu.edu.cn.

Received 15 September 2021

Accepted 16 September 2021

Published 13 October 2021

TABLE 1 Antimicrobial drug susceptibility profile

Drug	MIC (mg/liter) for:				
	HD6415 (parental strain)	EC600/pHD6415-NDM (transconjugant)	DH5 α /pET28a- <i>bla</i> _{NDM-5} (<i>bla</i> _{NDM-5} construct)	DH5 α /pET28a- <i>bla</i> _{NDM-33} (<i>bla</i> _{NDM-33} construct)	DH5 α /pET28a (empty vector)
Meropenem	512	64	32	64	0.125
Imipenem	512	256	256	512	0.125
Ertapenem	256	64	32	64	0.25
Ceftazidime	512	256	512	512	0.5
Aztreonam	4	0.125	0.125	0.125	0.125
Ceftazidime/Avibactam	512/4	256/4	256/4	64/4	0.25/4
Ciprofloxacin	32	0.125	0.125	0.125	0.125
Kanamycin	8	2	32	32	32
Tigecycline	1	0.5	0.5	0.5	0.5
Colistin	2	2	2	2	1

(3). In this study, we described a novel *bla*_{NDM-33} variant, identified from a multidrug-resistant *E. coli* strain, HD6415, from a hospital sewage sample.

The *E. coli* strain HD6415 was isolated from the sewage of the second affiliated hospital of Soochow University (Suzhou, China) in July 2019. We used LB plates containing 0.5 mg/liter meropenem for primary screening of sewage separated from each department in the hospital to study the distribution of CRE and further follow-up research. Bacterial antimicrobial susceptibility testing was performed using the broth microdilution method, and the results were interpreted according to the 2020 Clinical and Laboratory Standards Institute (CLSI) guidelines (4). The EUCAST (<http://www.eucast.org/>) breakpoints were used for colistin and tigecycline. The testing was performed in triplicates in two different days, and *Escherichia coli* ATCC 25922 was used as the quality control (QC) strain.

The strain HD6415 was resistant to most of the tested antimicrobial agents, including carbapenems (ertapenem, imipenem, and meropenem), ciprofloxacin, ceftazidime, and ceftazidime-avibactam. MICs of meropenem, ertapenem, and imipenem for HD6415 were 512, 256, and 512 mg/liter, respectively (Table 1). HD6415 was only susceptible to kanamycin (MIC = 8 mg/liter), tigecycline (MIC = 1 mg/liter), colistin (MIC = 2 mg/liter), and aztreonam (MIC = 4 mg/liter).

The presence of *bla*_{NDM} was initially determined by PCR (using primers ATGGAATTGCCCAATATTATGC [F] and TCAGCGCAGCTTGTCGG [R]) (5). Next-generation sequencing of the HD6415 genome was conducted using a paired-end library with an average insert size of 350 bp on a NovaSeq 6000 platform (Illumina, CA, USA). The raw reads were assembled *de novo* using SPAdes v3.11 (<http://cab.spbu.ru/software/spades/>). Further plasmid assembly was obtained by mapping contigs on reference sequences, checking overlapping paired ends, and confirming the assembly by the PCR-based gap closure method. The acquired antimicrobial resistance genes were identified using ResFinder 4.0 (6). *In silico* multilocus sequence typing (MLST; <https://cge.cbs.dtu.dk/services/MLST/>) showed HD6415 belonged to ST650. HD6415 contains genes encoding resistance to aminoglycosides [*aac(3)-IIa*, *aadA1*, and *aadA5*], β -lactams (*bla*_{OXA-1}, *bla*_{NDM-33}, and *bla*_{TEM-1}), phenicols (*floR* and *catA1*), tetracycline [*tet(A)* and *tet(B)*], fluoroquinolone (*qepA2* and *qnrS2*), and macrolide, lincosamide, and streptogramin B (MLS) [*mdf(A)*]. The mutations of *gyrA* (D87N; S83L) and *parC* (S80I) lead to the isolate being resistant to ciprofloxacin.

The *bla*_{NDM-33} variant showed a single-nucleotide difference (G214A) compared with *bla*_{NDM-5}, resulting in an amino acid substitution at codon 72 (A72T). The A72T amino acid substitution in NDM-33 was in the first active-site ring between the β 2 and β 3 chains, which shifted away from the Zn center to accommodate substrates with different molecular structures (7). Previous studies showed that base substitutions in this region did not affect the overall folding of the protein, but different thermal stabilities have been observed in NDM variants. NDM variants with double amino acid




FIG 1 Schematic diagram of the plasmid pHD6415-NDM. Genes of different functions are denoted by arrows and presented in various colors. The circles show (from outside to inside) predicted coding sequences, scale in 10 kb, backbone (black), and accessory module (gray) regions, GC content, and GC skew [(G-C)/(G+C)].

substitutions, e.g., NDM-8 (D130G, M154L), NDM-5 (V88L, M154L), and NDM-7 (D130N, M154L), appeared to be more stable to thermal denaturation than the singly substituted NDM-6 (A233V), NDM-3 (D95N), and NDM-4 (M154L) (8).

Currently, *bla*_{NDM} has been rapidly spreading in more than 40 countries worldwide through plasmids in different replicon types, including IncX3, IncF, IncN, IncA/C, IncR, and IncT (9, 10). Among them, IncX3 plasmid was a major vehicle in mediating the dissemination of *bla*_{NDM} in China (11). The genome sequence analysis showed *bla*_{NDM-33} was also carried by a 46.16-kb IncX3-type plasmid (pHD6415-NDM) (Fig. 1). *bla*_{NDM-33} was the only antimicrobial resistance gene presented on pHD6415-NDM, which was almost identical (100% query coverage and >99.9% nucleotide identities) to numerous IncX3-type plasmids carrying *bla*_{NDM}, such as pNDM5 (carrying *bla*_{NDM-5}; GenBank accession number [KU761328](#)), pJN05NDM7 (carrying *bla*_{NDM-7}; GenBank accession number [MH523639](#)), pNDM-20 (carrying *bla*_{NDM-20}; GenBank accession number [MF458176](#)), and pNDM21_020023 (carrying *bla*_{NDM-21}; GenBank accession number [CP025948](#)). Similar to the other *bla*_{NDM}-harboring IncX3 plasmids, *bla*_{NDM-33} was located in a Tn125-related element (Fig. 2), which was inserted within the backbone gene *umuD* of pHD6415-




FIG 2 Linear comparison of the *bla*_{NDM-33} region and related Tn125. Genes are denoted by arrows. Genes, mobile elements, and other features are colored based on their functional classification. Shading denotes regions of homology (nucleotide identity, $\geq 95\%$). Numbers in parentheses indicate nucleotide positions within the plasmid pHD6415-NDM. The accession number of Tn125 used as the reference is [JN872328](#) (14).

NDM and bracketed by the 3-bp direct repeats (DRs; target site duplication signals for transposition). This region was composed of multiple mobile genetic elements, including IS26, Δ Tn125, IS3000, and Δ Tn3.

To investigate the transferability of pHD6415-NDM, a conjugation experiment was carried out using the rifampin-resistant *E. coli* strain EC600 as the recipient. The transconjugant was selected on an LB agar plate containing 4 mg/liter meropenem and 200 mg/liter rifampin, and then the presence of *bla*_{NDM-33} in the transconjugant was confirmed by PCR and Sanger sequencing. Results showed *bla*_{NDM-33} can be successfully transferred via conjugation, with an efficiency of $\sim 1.2 \times 10^{-2}$ (transconjugant/recipient). Susceptibility testing showed that the transconjugant had meropenem, imipenem, and ertapenem MICs of 64, 256, and 64 mg/liter, respectively, in consistent with the carbapenem resistance phenotype observed in the parental strains (Table 1).

To further evaluate whether the A72T substitution in NDM-33 confers different levels of resistance to β -lactam antibiotics, we cloned the full-length *bla*_{NDM-33} and *bla*_{NDM-5} along with their identical natural promoters into the pET28a vector, followed by transformation into *E. coli* DH5 α cells. Meanwhile, the pET28a plasmid was transformed as a control (12). Susceptibility testing results showed that the carbapenem (ertapenem, imipenem, and meropenem) MICs in the *bla*_{NDM-33} construct (DH5 α /pET28a-*bla*_{NDM-33}) were 2-fold higher than those in the *bla*_{NDM-5} construct (DH5 α /pET28a-*bla*_{NDM-5}) (Table 1).

Steady-state enzyme kinetic parameters were performed for NDM-5 and NDM-33 as described previously (13). Briefly, the *bla*_{NDM-5} and *bla*_{NDM-33} gene sequences without the peptide signal region were amplified using primers EcoRI-NDM-F (5'-CCGGAATTCATG GAATTGCCCAATAT-3') and HindIII-NDM-R (5'-CCCAAGCTTTCAGCGCAGCTTGTCGGCC-3'), followed by cloning into the pET28a plasmid and transforming into *E. coli* BL21. The NDM-5 and NDM-33 enzymes were purified and suspended in the HEPES buffer (pH 7.5), containing 250 mM NaCl, 100 μ M ZnCl₂, 20 μ g/ml bovine serum albumin, at 25°C. The real-time absorbances of meropenem (298 nm), imipenem (297 nm), ceftazidime (257 nm), aztreonam (318 nm), cefotaxime (264 nm), cefepime (254 nm), piperacillin (232 nm), ceftazolin (270 nm), ceftriaxone (240 nm), and ampicillin (235 nm) were determined under initial-rate conditions with a Shimadzu UV2550 spectrophotometer (Kyoto, Japan). The results

TABLE 2 Steady-state enzyme kinetics of NDM-5 and NDM-33

Drug	NDM-5			NDM-33		
	K_m (μM)	k_{cat} (S^{-1})	k_{cat}/K_m ($\mu\text{M}^{-1}\cdot\text{S}^{-1}$)	K_m (μM)	k_{cat} (S^{-1})	k_{cat}/K_m ($\mu\text{M}^{-1}\cdot\text{S}^{-1}$)
Ampicillin	98	337.07	3.42	82	47.85	0.58
Imipenem	73	278.50	3.81	53	177.23	3.32
Meropenem	68	133.13	1.96	18	58.81	3.24
Cefazolin	163	84.97	0.52	64	266.18	4.14
Cefotaxime	38	146.68	3.81	32	64.80	2.05
Ceftazidime	30	107.71	3.58	68	77.85	1.15
Cefepime	34	77.34	2.29	103	54.48	0.53
Aztreonam	NH ^a	NH	NH	NH	NH	NH

^aNH, not detectable due to a low initial rate of hydrolysis.

showed that NDM-33 could hydrolyze all tested β -lactams except aztreonam (Table 2). The k_{cat}/K_m ratios for meropenem and cefazolin of NDM-33 were higher than those of NDM-5, but ceftazidime and cefepime k_{cat}/K_m ratios were lower than those of NDM-5. These results suggested that NDM-33 had higher enzymatic activity against meropenem and cefazolin and lower activity against ceftazidime and cefepime relative to NDM-5.

Taken together, our study described a novel NDM-33 variant from an *E. coli* strain isolated from hospital sewage. Hospital wastewater serves as an important reservoir for the emergence and transmission of antimicrobial resistance genes and variants, although it represents an environmental sample in which a high density of antibiotic residues and antibiotic-resistant bacteria are present. To some extent, the phenotypic differences between NDM-5 and NDM-33 are not remarkable. However, the continuous evolution of NDM enzymes could foster the emergence of novel variants that possess different hydrolysis activities toward β -lactam antibiotics. Our study enriched our understanding of enzymatic function and evidenced the ongoing evolution of NDM enzymes. A close surveillance of NDM-producing bacteria, both environmentally and clinically, should be enacted to monitor and control the spread of NDM variants.

Data availability. The draft whole-genome sequence of strain HD6415 was submitted to GenBank under accession number [JAGTHW000000000](https://www.ncbi.nlm.nih.gov/nuccore/JAGTHW000000000), and the complete sequence of plasmid pHD6415-NDM was submitted to GenBank under accession number [MZ004933](https://www.ncbi.nlm.nih.gov/nuccore/MZ004933).

ACKNOWLEDGMENTS

This study was supported by the Science Foundation of Jiangsu Province Health Department (ZDB2020014), the Discipline Construction Program of the Second Affiliated Hospital of Soochow University (XKTJ-TD202001), and Gusu Key Health Talent of Suzhou.

REFERENCES

- Perez-Vazquez M, Sola Campoy PJ, Ortega A, Bautista V, Monzon S, Ruiz-Carrascoso G, Mingorance J, Gonzalez-Barbera EM, Gimeno C, Aracil B, Saez D, Lara N, Fernandez S, Gonzalez-Lopez JJ, Campos J, Kingsley RA, Dougan G, Oteo-Iglesias J, Spanish NDM Study Group. 2019. Emergence of NDM-producing *Klebsiella pneumoniae* and *Escherichia coli* in Spain: phylogeny, resistome, virulence and plasmids encoding bla_{NDM}-like genes as determined by WGS. *J Antimicrob Chemother* 74:3489–3496. <https://doi.org/10.1093/jac/dkz366>.
- Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob Agents Chemother* 53:5046–5054. <https://doi.org/10.1128/AAC.00774-09>.
- Hornsey M, Phee L, Wareham DW. 2011. A novel variant, NDM-5, of the New Delhi metallo-beta-lactamase in a multidrug-resistant *Escherichia coli* ST648 isolate recovered from a patient in the United Kingdom. *Antimicrob Agents Chemother* 55:5952–5954. <https://doi.org/10.1128/AAC.05108-11>.
- Wayne P. 2020. Performance standards for antimicrobial susceptibility testing, 30th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.
- Poirel L, Walsh TR, Cuvillier V, Nordmann P. 2011. Multiplex PCR for detection of acquired carbapenemase genes. *Diagn Microbiol Infect Dis* 70: 119–123. <https://doi.org/10.1016/j.diagmicrobio.2010.12.002>.
- Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL, Rebelo AR, Florensa AF, Fagelhauer L, Chakraborty T, Neumann B, Werner G, Bender JK, Stingl K, Nguyen M, Coppens J, Xavier BB, Malhotra-Kumar S, Westh H, Pinholt M, Anjum MF, Duggett NA, Kempf I, Nykasanova S, Olkkola S, Wiczorek K, Amaro A, Clemente L, Mossong J, Losch S, Ragimbeau C, Lund O, Aarestrup FM. 2020. ResFinder 4.0 for predictions of phenotypes from genotypes. *J Antimicrob Chemother* 75: 3491–3500. <https://doi.org/10.1093/jac/dkaa345>.
- Khan S, Ali A, Khan AU. 2018. Structural and functional insight of New Delhi metallo beta-lactamase-1 variants. *Future Med Chem* 10:221–229. <https://doi.org/10.4155/fmc-2017-0143>.

8. Makena A, Brem J, Pfeffer I, Geffen RE, Wilkins SE, Tarhonskaya H, Flashman E, Phee LM, Wareham DW, Schofield CJ. 2015. Biochemical characterization of New Delhi metallo-beta-lactamase variants reveals differences in protein stability. *J Antimicrob Chemother* 70:463–469. <https://doi.org/10.1093/jac/dku403>.
9. Yasmin M, Fouts DE, Jacobs MR, Haydar H, Marshall SH, White R, D'Souza R, Lodise TP, Rhoads DD, Hujer AM, Rojas LJ, Hoyen C, Perez F, Edwards A, Bonomo RA. 2020. Monitoring ceftazidime-avibactam and aztreonam concentrations in the treatment of a bloodstream infection caused by a multidrug-resistant *Enterobacter* sp. carrying both *Klebsiella pneumoniae* carbapenemase-4 and New Delhi metallo-beta-lactamase-1. *Clin Infect Dis* 71:1095–1098. <https://doi.org/10.1093/cid/ciz1155>.
10. Zhu Y, Liu W, Schwarz S, Wang C, Yang Q, Luan T, Wang L, Liu S, Zhang W. 2020. Characterization of a blaNDM-1-carrying IncHI5 plasmid from *Enterobacter cloacae* complex of food-producing animal origin. *J Antimicrob Chemother* 75:1140–1145. <https://doi.org/10.1093/jac/dkaa010>.
11. Wu W, Feng Y, Tang G, Qiao F, McNally A, Zong Z. 2019. NDM metallo-beta-lactamases and their bacterial producers in health care settings. *Clin Microbiol Rev* 32:e00115-18. <https://doi.org/10.1128/CMR.00115-18>.
12. Liu L, Feng Y, McNally A, Zong Z. 2018. blaNDM-21, a new variant of blaNDM in an *Escherichia coli* clinical isolate carrying blaCTX-M-55 and rmtB. *J Antimicrob Chemother* 73:2336–2339. <https://doi.org/10.1093/jac/dky226>.
13. Ali A, Gupta D, Srivastava G, Sharma A, Khan AU. 2019. Molecular and computational approaches to understand resistance of New Delhi metallo beta-lactamase variants (NDM-1, NDM-4, NDM-5, NDM-6, NDM-7)-producing strains against carbapenems. *J Biomol Struct Dyn* 37:2061–2071. <https://doi.org/10.1080/07391102.2018.1475261>.
14. Poirel L, Bonnin RA, Boulanger A, Schrenzel J, Kaase M, Nordmann P. 2012. Tn125-related acquisition of blaNDM-like genes in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 56:1087–1089. <https://doi.org/10.1128/AAC.05620-11>.